Anxin Medical Completes Tens-of-Millions RMB Angel Round to Accelerate Expansion in Women's Health Sector

VCBeat has learned that, recently,Guangdong Anxin Medical Technology Co., Ltd. (hereinafter referred to as “Anxin Medical”) has announced the completion of its angel financing round, raising tens of millions of RMB. The round was led by Haiyuan Capital, with Dongke Chuang Capital participating as a co-investor, and Jiangpan Capital serving as the exclusive long-term financial advisor. The proceeds from this financing will be primarily allocated to the regulatory registration and approval of the company’s core products, the upgrading of its production system and distributor network, and the establishment of an expert promotion framework, thereby further consolidating the company’s competitive advantages in the field of minimally invasive gynecological diagnosis and treatment.

Anxin Medical, established in 2023, specializes in the research and development, manufacturing, and sales of medical devices for women’s health. Centered on a complete therapeutic loop encompassing “preoperative diagnosis–intraoperative treatment–postoperative rehabilitation,” the company continuously refines its product portfolio spanning from diagnosis to treatment and from surgery to recovery. It has built systematic solutions covering active equipment, single-use instruments, high- and low-value consumables, and consumer-oriented products, with a commitment to enhancing the precision and efficiency of gynecological diagnosis and treatment.

Currently, the gynecological minimally invasive diagnosis and treatment market, representing women's health, is witnessing unprecedented growth opportunities.

According to data from the "China Health and Family Planning Statistical Yearbook," the annual number of outpatient visits in obstetrics and gynecology in China has reached 500-600 million. Given a female population base of less than 700 million, this figure fully highlights the widespread and urgent demand for diagnosis and treatment in this field. However, in contrast to the robust clinical demand, this sector has long been dominated by overseas manufacturers, with core technologies and high-end equipment heavily reliant on imports. This not only results in high procurement costs and low technology penetration but also underscores issues such as insufficient clinical adaptability.

Against this backdrop, the triple drivers of policy, society, and technology are jointly propelling industry transformation.

First, the state strongly supports the “import substitution” of high-end medical equipment at the policy level, opening up broad development space for domestic enterprises; second, the growing awareness of health management among the general public and women has given rise to substantial unmet clinical needs; finally, the rapid iteration of technology itself and the continuous expansion of application scenarios are constantly creating new blue-ocean markets.

These ongoing changes are presenting a historic opportunity for domestic enterprises with clinical insights and technological innovation capabilities, reshaping the industry landscape.

As a pioneer in minimally invasive gynecological technology in China, Anxin Medical has always placed strategic emphasis on women’s holistic health, focusing its product portfolio on “import substitution” and “integrated diagnosis and treatment,” and is committed to providing women with more cost-effective, safer, and more accessible diagnostic and therapeutic products and services.

The company has assembled a multidisciplinary team that combines clinical insight, technical implementation capabilities, market acumen, and sales execution excellence, with core members averaging over 10 years of industry experience. Leveraging the team’s extensive expertise, Jiangsu Anxin Medical Technology Co., Ltd. has secured multiple invention patents and established in-depth collaborations with numerous key hospitals and clinical experts.

Building on this foundation, Jiangsu Anxin Medical Technology Co., Ltd. further leverages its tripartite strategy of “market-driven growth, channel synergy, and product innovation” to continuously expand its influence in both the market and academic spheres.

In terms of market-driven growth, the company’s products have covered more than 20 provinces across China and over 100 core hospitals, establishing a commercial closed loop of “academia-driven market expansion.” By organizing high-frequency, high-level academic conferences, collaborating on clinical pathways, and promoting expert consensus, the company has deeply integrated with clinical expert resources to continuously drive market expansion.

In terms of channel synergy, the company not only provides domestic and international physicians with more efficient and convenient diagnostic and therapeutic tools to achieve extensive regional coverage, but also actively organizes professional training activities such as the “Anxin Cup Hysteroscopy Skills Competition” and “Xinyue Xiangfeng.” These initiatives promote the deep integration of clinical education and brand value while driving the collective advancement of gynecological medicine.

In October 2025, the State Council Information Office pointed out in the white paper *Practice and Achievements of China’s Promotion of Women’s Comprehensive Development in the New Era* that women’s health is the cornerstone of their comprehensive development, and emphasized taking maternal and child health as a core indicator to channel various resources toward the field of women’s health. This top-level design of the national strategy has brought unprecedented policy dividends to the women’s health market, with the industry entering a period of rapid growth opportunities.

Driven by both this policy guidance and market opportunities, Jiangsu Anxin Medical Technology Co., Ltd. will adhere to its “clinical-centered, patient-oriented” philosophy, continuously advance the registration and mass production of its core products, strengthen its expert training system, and accelerate its overseas market expansion and the R&D of second-generation core technologies. The company aims to build a globally competitive women’s health brand, enabling more people to benefit from the health advantages offered by modern minimally invasive gynecological diagnosis and treatment technologies.

For this round of financing,Liu Lei, Founder and CEO of Anxin MedicalStatement: We extend our gratitude to Haiyuan Capital and Dongke Chuang Capital for their investment, as well as to Jiangpan Capital for its support. This round of financing represents a dual recognition by the investment community of both the value inherent in the women’s health sector and the capabilities of the Anxin team. We are especially grateful to our founding team for their perseverance and breakthroughs—from overcoming technical barriers to achieve import substitution, to expanding product coverage to over one hundred core hospitals. Guided by a profound respect for women’s health, the team has leveraged more than a decade of industry experience to build robust product strength. This has enabled us to focus on addressing diagnostic and therapeutic pain points across the entire “pre-operative, intra-operative, and post-operative” continuum, strengthening the defense line for female fertility preservation by optimizing device safety and refining precise diagnostic solutions. Looking ahead, we will allocate the funds toward regulatory registration and mass production of our core products, as well as R&D for next-generation technologies. Through technological breakthroughs, we aim to make fertility preservation more proactive and effective in the diagnosis and treatment of critical diseases. Simultaneously, we will enhance our training system to disseminate the concept of fertility preservation and appropriate technologies to physicians. We will also accelerate our overseas expansion, striving to serve as a “clinical assistant” to doctors and a “health partner” to women. As we grow into a brand with international competitiveness, we remain committed to contributing to the innovative development of the women’s health industry.

Zhao Yuanyuan, Partner at Haiyuan CapitalIt stated that the decision to invest in Anxin Medical was driven not only by optimism about the blue-ocean prospects of the innovative gynecological device sector, but also by recognition of the company’s “clinical-need-oriented” product strategy and the comprehensive strength of its team. Leveraging its full-scenario product portfolio, independently controlled core technologies, market-aligned cost advantages, and an “academia-driven market” commercialization pathway, Anxin Medical is well-positioned to address the challenges facing the gynecology industry, promote the adoption and widespread use of domestically produced innovative gynecological devices, benefit patients, and emerge as an innovation leader in the gynecological sector.

Zou Jingjie, Early-Stage Biopharmaceutical Project Investor at Dongke Venture CapitalIt demonstrates that the Anxin Medical team possesses both interdisciplinary technical expertise and robust industrialization capabilities. By precisely addressing the clinical challenges in diagnosing and treating intrauterine gynecological diseases, and through deep integration of medicine and engineering, Anxin Medical continuously refines its comprehensive gynecological solutions. It has established a full-chain innovation ecosystem covering high-end equipment, supporting consumables, technology transfer, and market application. Meanwhile, Anxin Medical actively leverages high-level professional competitions to deepen clinical education, building the image of domestic brands while relying on a mature sales network to drive in-depth market expansion. The investment by Dongguan Songshan Lake in Anxin Medical is one of the measures taken by Dongguan Sci-Tech Finance Group to thoroughly implement Dongguan’s “8+8+4” modern industrial system strategy and accelerate the cultivation of strategic emerging clusters in biomedicine and general health. This move holds significant importance for further improving the gradient ecosystem of the medical device industry in Dongguan Songshan Lake.

Chen Xiang, Partner and Head of Healthcare at Jiangpan CapitalStatement: We are deeply honored to serve as the exclusive financial advisor for Anxin Medical’s current round of financing. Women’s health is a sector that has long been undervalued but is now encountering structural opportunities. As global population aging and declining birth rates become increasingly prominent, societal emphasis on women’s health management continues to rise, positioning women’s medical devices and diagnostic and therapeutic services as the next major growth pole for the industry. Against this backdrop, numerous leading domestic and international medical device companies are intensifying their investments in the women’s health sector, with significantly heightened attention from both policymakers and investors. As one of the representative enterprises in China’s women’s health industry, Jiangsu Anxin Medical Technology Co., Ltd. boasts a team with decades of deep industry engagement, possessing a profound understanding of product development and clinical needs. The company has demonstrated strong capabilities in industry insight, product innovation, and commercial execution. We believe that with the continued rollout of its core products and market expansion, Anxin Medical is destined to grow into a benchmark enterprise in the field of women’s health.

Haiyuan Capital was established in 2014. Its main initiators possess an average of approximately 20 years of experience in investment and corporate management, along with profound backgrounds in engineering and technology, forming a team of value-added investment managers. To date, Haiyuan Capital has completed investments in nearly 120 hard-tech projects. Advocating an international perspective, the Haiyuan team currently focuses on global hard-tech investments through its Hong Kong-based fund. The company manages assets under management exceeding RMB 7 billion. It has successfully invested in numerous high-quality enterprises, including JPT (SH688025), Shinry Technology (SZ300745), Harbour Biomed (02142.HK), MicroTech Medical (02235.HK), Wavelength Opto-Electronic (SZ301421), Lianlian DigiTech (02598.HK), Ait Network Energy (acquired), Shankan Pharmaceutical, Hengrui Yuanzheng, Nurotron, Burui Technology, Xinhai Biology, Ruihua Pharmaceutical, Yuanxing Gene, Rouling Technology, Taiyan Semiconductor, Qier Electromechanical, Elephant Sound, Muwang Technology, Linhuiba, Beiteli, Huasixu, Bohua New Energy, Yonglian Technology, Saisi Electronics, Anko Technology, Xinfei Optical Communication, Shisenhai Medicine, Jingdan Biology, and Yurucheng. Its investment portfolio spans integrated circuits, intelligent manufacturing, healthcare, new materials, TMT, and artificial intelligence.

The Municipal Technology Achievement Transformation Fund was established with capital contributions from the Dongguan Angel Fund of Funds. The Dongguan Science and Technology Bureau serves as the competent authority for the fund, while the Sci-Tech Innovation Group acts as the fund manager. With an initial scale of RMB 100 million, it is the city’s first policy-oriented fund focused on technology achievement transformation projects. This initiative represents a key action by the Sci-Tech Innovation Group to implement the central, provincial, and municipal directives on deeply promoting the conversion of scientific and technological achievements into real productive forces, and to support the Dongguan Science and Technology Bureau in executing the “Three-Year Action Plan for Accelerating the Industrialization of Scientific and Technological Achievements in Dongguan (2025–2027).” The fund will invest exclusively in seed-stage and early-stage projects, prioritizing Dongguan’s “8+4” strategic emerging and future industry layout. Aimed at resolving the “last mile” challenge in transforming university research outcomes into practical applications, the fund will rapidly channel resources into technological achievement projects in Dongguan that demonstrate strong technical competitiveness and promising industrialization prospects.

Dongguan Sci-Tech Innovation Capital is the equity investment arm of Dongguan Sci-Tech Innovation Group, operating through its wholly-owned subsidiary, Dongguan Sci-Tech Innovation Capital Investment Management Co., Ltd., which holds a “Private Fund Manager” license. Focusing on “technological innovation + advanced manufacturing” and aligning with the city’s “8+4+4” key industrial sectors, it has established a comprehensive, full-lifecycle investment and financing service system covering angel investing, venture capital (VC), private equity (PE), strategic placements, and private placements. Currently, it manages the Dongguan Mass Entrepreneurship and Innovation Fund of Funds and the Municipal Angel Fund of Funds. In collaboration with the Dongguan Science and Technology Bureau, the Municipal Market Supervision Administration, and multiple towns and sub-districts, it has set up 45 funds, including specialized industry funds such as the Dongguan Intellectual Property Fund, the Specialized and Sophisticated SMEs Fund, the Sci-Tech Tangxia Fund, the Sci-Tech Wanjiang Fund, the Sci-Tech Houjie Fund, and the Songshan Lake Angel Fund, as well as the Sci-Tech Towns and Sub-districts series.

Jiangpan Capital, established in 2024 and headquartered in Shanghai, is a professional institution focused on the healthcare and wellness sector. The company’s core business activities include private equity financing, corporate business enablement, and secondary share exits. Its team comprises professionals from leading industry institutions, bringing deep expertise and extensive project experience. Jiangpan Capital is committed to providing high-quality, customized capital market services to healthcare enterprises, facilitating their sustained growth and value enhancement.